Joel McMillan

Joel McMillan

Auto-generated profile, based on publicly available information

Joel McMillan

Department of Urology and Center for Clinical Research, University of Freiburg Medical Center, 79106, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2016 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
EMEric Metzger
Eric Metzger
DWDominica Willmann
Dominica Willmann
JMJoel McMillan
Joel McMillan
IFIgnasi Forne
Ignasi Forne
PMPhilipp Metzger
Philipp Metzger
RSRoland Schüle
Roland Schüle

17 February 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
TWTobias Wagner
Tobias Wagner
HGHolger Greschik
Holger Greschik
TBTeresa Burgahn
Teresa Burgahn
KSKarin Schmidtkunz
Karin Schmidtkunz
ASAnne-Kathrin Schott
Anne-Kathrin Schott
MJManfred Jung
Manfred Jung
Epigenetic modifications of histone tails play an essential role in the regulation of eukaryotic transcription. Writer and eraser enzymes establish and maintain the epigenetic code by creating or removing posttranslational marks. Specific binding proteins, called readers, recognize the modifications and mediate epigenetic signalling. Here, we present a versatile assay platform for the investigation of the interaction between methyl lysine readers and their ligands. This can be utilized for the screening of small-molecule inhibitors of such protein–protein interactions and the detailed characterization of the inhibition. Our platform is constructed in a modular way consisting of orthogonal in vitro binding assays for ligand screening and verification of initial hits and biophysical, label-free techniques for further kinetic characterization of confirmed ligands. A stability assay for the investigation of target engagement in a cellular context complements the platform. We applied the complete evaluation chain to the Tudor domain containing protein Spindlin1 and established the in vitro test systems for the double Tudor domain of the histone demethylase JMJD2C. We finally conducted an exploratory screen for inhibitors of the interaction between Spindlin1 and H3K4me3 and identified A366 as the first nanomolar small-molecule ligand of a Tudor domain containing methyl lysine reader.

16 September 2016 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
DRDina Robaa
Dina Robaa
TWTobias Wagner
Tobias Wagner
CLChiara Luise
Chiara Luise
LCLuca Carlino
Luca Carlino
JMJoel McMillan
Joel McMillan
Wolfgang SipplWolfgang Sippl
Wolfgang Sippl